Immatics Selling General Administrative from 2010 to 2024

IMTXW Stock  USD 0.34  0.08  19.05%   
Immatics Biotechnologies Selling General Administrative yearly trend continues to be fairly stable with very little volatility. Selling General Administrative will likely drop to about 29.7 M in 2024. During the period from 2010 to 2024, Immatics Biotechnologies Selling General Administrative regression line of quarterly data had mean square error of 57.9 T and geometric mean of  12,993,987. View All Fundamentals
 
Selling General Administrative  
First Reported
2018-03-31
Previous Quarter
10.1 M
Current Value
11.2 M
Quarterly Volatility
3.3 M
 
Covid
Check Immatics Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics Biotechnologies' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 13.7 M or Interest Income of 14.5 M, as well as many indicators such as Price To Sales Ratio of 13.5, Dividend Yield of 0.0 or PTB Ratio of 3.58. Immatics financial statements analysis is a perfect complement when working with Immatics Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Immatics Biotechnologies Correlation against competitors.

Latest Immatics Biotechnologies' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of immatics biotechnologies GmbH over the last few years. It is Immatics Biotechnologies' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Immatics Selling General Administrative Regression Statistics

Arithmetic Mean16,847,864
Geometric Mean12,993,987
Coefficient Of Variation77.13
Mean Deviation11,697,153
Median7,666,000
Standard Deviation12,995,292
Sample Variance168.9T
Range30.5M
R-Value0.83
Mean Square Error57.9T
R-Squared0.68
Significance0.0002
Slope2,398,899
Total Sum of Squares2364.3T

Immatics Selling General Administrative History

202429.7 M
202338.2 M
202236.1 M
202133.8 M
202034.2 M
201911.8 M

About Immatics Biotechnologies Financial Statements

Immatics Biotechnologies investors use historical fundamental indicators, such as Immatics Biotechnologies' Selling General Administrative, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immatics Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative38.2 M29.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immatics Stock Analysis

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.